GUJTHEM
Gujarat Themis Biosyn Limited Announces Strategic Acquisition of Microbiopharm Japan
Gujarat Themis Biosyn Limited (GUJTHEM) announces acquisition of MicroBiopharm Japan, enhancing its fermentation capabilities and expanding its CDMO services.
Gujarat Themis Biosyn Limited (GUJTHEM) announced the acquisition of MicroBiopharm Japan (MBJ), a strategic move aimed at enhancing its fermentation capabilities and expanding its contract development and manufacturing (CDMO) services. The acquisition, valued at JPY 9.5 Bn (INR 557 Cr), is expected to bolster GUJTHEM’s position in the global pharmaceutical market.
Enhanced Fermentation Capabilities
The acquisition of MBJ will provide GUJTHEM access to advanced fermentation, bio-conversion, and precision fermentation technologies. This will enable GUJTHEM to expand its product portfolio to include fermentation-based immunosuppressants, oncology APIs, and anti-infectives.
Diversified Product Portfolio
With the integration of MBJ’s technologies, GUJTHEM aims to transition from anti-TB and anti-infective APIs to specialty small molecules, biologics, and gene therapy products. This diversification will create multiple revenue streams, enhancing the company’s long-term growth prospects.
Global Expansion
The acquisition will also provide GUJTHEM with a global platform, leveraging MBJ’s established customer relationships and manufacturing base in Japan. This will facilitate market entry into Europe and the US, particularly in the plasmid market and CDMO services for immunosuppressants and precision fermentation.
Source: NSE Corporate Announcement
Fundamental & Technical Analysis of Gujarat Themis Biosyn Limited
Gujarat Themis Biosyn Limited belongs to the Healthcare › Drug Manufacturers – Specialty & Generic sector. Here’s a quick read on where the business and the stock stand today.
Gujarat posts a 11.4% three-month gain, but softens in the last few weeks. Industry-leading margins of 28.0% reflect exceptional pricing power and operational efficiency. Revenue contracts at 3.8% CAGR. That signals structural headwinds, not a short-term blip. The stock gives back 0.1% in the last month despite a positive three-month run. As a result, the earlier momentum appears to be fading. Revenue grows at 3.8% and the stock moves sideways over three months. Neither side makes a strong case. The next earnings print will likely break this stock out of its current range. Check Fundamentals of Gujarat Themis Biosyn Limited.
GUJTHEM
Gujarat Themis Biosyn Limited Q2 FY27: Revenue Up 12% Yoy, New Facility Commissioned
Gujarat Themis Biosyn Limited (GUJTHEM) reports Q2 FY27 revenue up 12% YoY, new fermentation facility commissioned.
Gujarat Themis Biosyn Limited (GUJTHEM) has reported robust financial results for Q2 FY27, with standalone revenue growing 12% year-on-year to Rs. 47.5 crore. The growth was primarily driven by strong volume momentum and a favorable shift in product mix towards Active Pharmaceutical Ingredients (APIs). The company’s new fermentation facility, commissioned during the quarter, marks a significant milestone in strengthening its manufacturing capabilities. Although the commissioning phase has had a near-term impact on operating margins, benefits from augmented capacity utilization are expected to become increasingly visible from Q4 FY27 onwards.
Quarterly Financial Highlights
During Q2 FY27, the company’s EBITDA stood at Rs. 8.5 crore, down 15.3% year-on-year, while EBITDA margins decreased by 1,210 basis points to 17.8%. The profit after tax (PAT) was Rs. 8.5 crore, down 40.6% YoY, with PAT margins dropping by 1,584 basis points to 17.8%. The company’s earnings per share (EPS) stood at Rs. 0.65 compared to Rs. 1.31 in the same quarter last year.
Half-Yearly Financial Performance
For H1 FY27, the company’s revenue grew 17% year-on-year to Rs. 91 crore. EBITDA increased 11% to Rs. 39 crore, while EBITDA margins declined by 235 basis points to 42.2%. The PAT for H1 FY27 was Rs. 19.5 crore, down 16.3% YoY, with PAT margins decreasing by 841 basis points to 21.4%. The EPS for H1 FY27 was Rs. 1.50 compared to Rs. 2.14 in the same period last year.
Dr. Sachin Patel, Managing Director, commented on the results, stating, ‘We are pleased to have commenced FY27 with healthy business momentum. As the new capacity moves towards higher utilization and the benefits of the acquisition begin to flow through, we expect operating performance to strengthen progressively. Our strategic priorities remain centered around precision fermentation, bioconversion, gene therapy, anti-infectives, and biopeptides, supported by capacity utilization, R&D-led product development, and a continued focus on operational efficiency. We believe these initiatives provide a strong platform for sustainable growth and value creation over the medium to long term.’
Source: NSE Corporate Announcement
Fundamental & Technical Analysis of Gujarat Themis Biosyn Limited
Gujarat Themis Biosyn Limited belongs to the Healthcare › Drug Manufacturers – Specialty & Generic sector. Here’s a quick read on where the business and the stock stand today.
Gujarat posts a 11.4% three-month gain, but softens in the last few weeks. Industry-leading margins of 28.0% reflect exceptional pricing power and operational efficiency. Revenue contracts at 3.8% CAGR. That signals structural headwinds, not a short-term blip. The stock gives back 0.1% in the last month despite a positive three-month run. As a result, the earlier momentum appears to be fading. Revenue grows at 3.8% and the stock moves sideways over three months. Neither side makes a strong case. The next earnings print will likely break this stock out of its current range. Check Fundamentals of Gujarat Themis Biosyn Limited.
GUJTHEM
Gujarat Themis Biosyn Limited (gujthem) Q1 FY27: Topline Surges 22%, PAT Improves 22%
Gujarat Themis Biosyn Limited (GUJTHEM) reports a 22% year-on-year topline surge to Rs. 43.8 crores in Q1 FY27.
Gujarat Themis Biosyn Limited (GUJTHEM) has reported robust financial results for Q1 FY27, marking a significant growth trajectory for the company. The topline surged 22.1% year-on-year to Rs. 43.8 crores, driven by healthy sales volumes and stable demand in the market. The company’s profit after tax (PAT) also improved by 22.1% to Rs. 11.1 crores, reflecting strong operational performance and improved margins.
Strategic Acquisitions Boost Growth
GUJTHEM’s strategic acquisitions have played a crucial role in its growth. The acquisition of MicroBiopharm in Japan, valued at JPY 21.5 Bn (~INR 1,300 Crore), is expected to broaden the company’s therapeutic coverage and enhance its manufacturing capabilities. Additionally, the agreement with Sanofi to acquire select product portfolios for ~EUR 158 Mn provides immediate global market access and established brand equity.
Operational Highlights
The company’s EBITDA increased by 49.4% to Rs. 20.8 crores, driven by economies of scale due to higher volumes. The EBITDA margin improved significantly, reflecting the company’s efficient operational model. The earnings per share (EPS) for the quarter stood at Rs. 1.02, indicating strong shareholder value creation.
GUJTHEM continues to focus on expanding its global footprint and technological capabilities. The development of new R&D and API units, along with the completion of a new fermentation facility, positions the company for sustained growth and operational efficiency. The hybrid power plant in Gujarat is expected to reduce power costs and lower the company’s carbon footprint, supporting environmental sustainability.
Source: NSE Corporate Announcement
Fundamental & Technical Analysis of Gujarat Themis Biosyn Limited
Gujarat Themis Biosyn Limited belongs to the Healthcare › Drug Manufacturers – Specialty & Generic sector. Here’s a quick read on where the business and the stock stand today.
Gujarat falls 10.7% over three months and has not found a floor yet. Industry-leading margins of 28.2% reflect exceptional pricing power and operational efficiency. Revenue contracts at 3.8% CAGR. That signals structural headwinds, not a short-term blip. Sellers drive 1.5x the volume of buyers. Furthermore, they controlled 16 of recent sessions versus 14 for buyers — a clear distribution signal. Revenue grows at 3.8% CAGR — a respectable pace. However, the stock drops 10.7% in three months without an obvious fundamental trigger. Sector-wide pressure or a valuation re-rating can persist for longer than expected. Therefore, there is no rush to step in. Check Fundamentals of Gujarat Themis Biosyn Limited.
GUJTHEM
Gujarat Themis Biosyn Limited Announces Strategic Acquisitions and Expansion Plans
Gujarat Themis Biosyn Limited (GUJTHEM) announces strategic acquisitions and expansion plans, including MicroBiopharm Japan and Sanofi’s product portfolio.
Gujarat Themis Biosyn Limited (GUJTHEM) has announced significant strategic acquisitions and expansion plans for FY27, marking a pivotal phase in its growth trajectory. The company has entered into agreements to acquire MicroBiopharm Japan and Sanofi’s select product portfolio, both of which are subject to regulatory approvals.
Acquisition of MicroBiopharm Japan
GUJTHEM has announced the acquisition of MicroBiopharm Japan Co. Ltd., a fermentation-based immunosuppressants and oncology APIs manufacturer. This acquisition, valued at JPY 9.5 Bn (INR 561.82 Crs), will enhance GTBL’s fermentation and precision biotech capabilities, expanding its product portfolio to include advanced biologics and novel modalities.
Acquisition of Sanofi’s Select Product Portfolio
GUJTHEM has also agreed to acquire Sanofi’s anti-tuberculosis and anti-infectives portfolio. This €158 mn deal will provide GTBL with a comprehensive portfolio of mature brands for treating tuberculosis and other infections, significantly expanding its market presence in Europe, the Middle East, and Africa.
Strategic Rationale and Future Growth
The acquisitions are expected to unlock immediate geographical expansion, forward integration, and margin enhancement. With a strong focus on Europe and Middle East & Africa, GUJTHEM aims to leverage its established brand equity and technological prowess to drive future growth.
Source: NSE Corporate Announcement
Fundamental & Technical Analysis of Gujarat Themis Biosyn Limited
Gujarat Themis Biosyn Limited belongs to the Healthcare › Drug Manufacturers – Specialty & Generic sector. Here’s a quick read on where the business and the stock stand today.
Gujarat posts a 69.3% three-month gain, but softens in the last few weeks. Industry-leading margins of 28.2% reflect exceptional pricing power and operational efficiency. Revenue contracts at 3.8% CAGR. That signals structural headwinds, not a short-term blip. The stock gives back 5.0% in the last month despite a positive three-month run. As a result, the earlier momentum appears to be fading. The stock rises 69.3% in three months on 3.8% revenue growth. As a result, the market gives it more credit than the fundamentals strictly justify. Watch the next quarterly results. If growth accelerates, the move makes sense. If not, expect some gains to unwind. Check Fundamentals of Gujarat Themis Biosyn Limited.
-
Financial Services3 days agoSammaan Capital Limited (sammaancap) Q2 FY27: Disbursements Rise 62% Qoq and PAT Grows 28%
-
Capital Markets3 days agoMaster Trust Limited (mastertr): Mastercapitalservices Raises ₹75 Cr Through Ncds
-
Consumer Cyclical3 days agoSenco Gold Limited (senco) Investor Presentation Q2 & H1 FY27 Highlights
-
Healthcare3 days agoZydus Lifesciences Limited (zyduslife) Inspection by USFDA Concludes at Liqmeds, UK
-
MAXESTATES2 days agoMax Estates Limited (maxestates) Reimagines Luxury Living Through ‘the Bungalows’
-
Financial Services3 days agoSammaan Capital Limited (sammaancap) Q2fy27 Investor Presentation: Strong Growth and Expansion
-
Basic Materials3 days agoGalaxy Surfactants Limited (galaxysurf) Signs Mou with LG Electronics for Sustainable Cleaning Solutions
-
Consumer Cyclical3 days agoSenco Gold Limited (senco) Q2 FY27: Revenue Growth of 34%, Retail Expansion Adds 14 Showrooms
